A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington’s disease

Background Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin ( HTT ) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuroinflammation Jg. 19; H. 1; S. 56 - 17
Hauptverfasser:	Chen, Kai-Po, Hua, Kuo-Feng, Tsai, Fu-Ting, Lin, Ting-Yu, Cheng, Chih-Yuan, Yang, Ding-I., Hsu, Hsien-Ta, Ju, Tz-Chuen
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 26.02.2022 BioMed Central Ltd BMC
Schlagworte:	Animals Biomedical and Life Sciences Biomedicine Disease Models, Animal Genetic aspects Huntington Disease - drug therapy Huntington Disease - genetics Huntington Disease - metabolism Huntington's chorea Huntington’s disease (HD) Immunology Inflammasomes - therapeutic use Interleukin‐1β (IL‐1β) Male Mice Mice, Transgenic Mutated huntingtin (mHTT) Neurobiology Neurodegenerative Diseases Neurology Neuroprotection Neurosciences NLR Family, Pyrin Domain-Containing 3 Protein - metabolism Nucleotide oligomerization domain-like receptor protein 3 inflammasome (NLRP3 inflammasome) Patient outcomes Prevention Taiwan Nucleotide oligomerization domain-like receptor protein 3 inflammasome (NLRP3 inflammasome) Huntington’s disease (HD) Interleukin‐1β (IL‐1β) Mutated huntingtin (mHTT)
ISSN:	1742-2094, 1742-2094
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!